Back to today’s briefing

Story perspectives

CAR T-Cell Therapy Shows 96% Response Rate, Faces Challenges

6/15/2025

47 5

Summary

Story summary

In an exciting breakthrough, the phase 1b trial of JNJ’4496, a CAR T-cell therapy for relapsed large B-cell lymphoma, revealed a remarkable 96% overall response rate. However, the journey isn't without challenges, as many participants faced significant side effects like neutropenia and cytokine release syndrome. Despite these hurdles, the path forward for further development looks promising.

1 of 1

Story summary

In an exciting breakthrough, the phase 1b trial of JNJ’4496, a CAR T-cell therapy for relapsed large B-cell lymphoma, revealed a remarkable 96% overall response rate. However, the journey isn't without challenges, as many participants faced significant side effects like neutropenia and cytokine release syndrome. Despite these hurdles, the path forward for further development looks promising.